| Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
| 公開日 |
2017-02-14 |
| タイトル |
|
|
タイトル |
Pleiotropic Effects of Linagliptin Monotherapy on Levels of Nitric Oxide, Nitric Oxide Synthase, and Superoxide Dismutase in Hemodialysis Patients with Diabetes |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
| 著者 |
KIMURA, Kengo
NAKAMURA, Yuya
HASEGAWA, Hitomi
TSUJI, Mayumi
OGUCHI, Tatsunori
TSUCHIYA, Hiromichi
GOTOH, Hiromichi
GOTO, Yoshikazu
INAGAKI, Masahiro
OGUCHI, Katsuji
|
| 書誌情報 |
The Showa University journal of medical sciences
巻 28,
号 1,
p. 9-17,
発行日 2016-03
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Linagliptin is an anti-diabetic drug and the only bile-excreted dipeptidyl peptidase-4 inhibitor. Malnutrition-inflammation-atherosclerosis syndrome is an important prognostic factor for hemodialysis patients, and we previously reported anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. Inflammation can accelerate oxidative stress, vasoconstriction, and platelet aggregation. However, few studies have investigated the pleiotropic effects of linagliptin treatment on inflammation in hemodialysis patients. In this study, we have extended our previous investigations of these effects in a longer and more thorough follow-up of hemodialysis patients with diabetes. We examined 20 hemodialysis patients with diabetes who were not receiving oral diabetes drugs or insulin therapy and who exhibited inadequate glycemic control (glycated albumin levels＞20%). Linagliptin (5mg) was administered daily, and we evaluated the patients’ superoxide dismutase, 8-hydroxydeoxyguanosine, nitric oxide, nitric oxide synthase, and asymmetric dimethylarginine levels in serum at baseline and after 1, 3, and 6 months of treatment. After 6 months of treatment, superoxide dismutase levels had significantly decreased from 8.8±0.5U/ml to 7.0±0.5U/ml. Nitric oxide synthase levels were significantly increased at 3 and 6 months (maximum, 94.2±13.2µg/ml; baseline, 31.6±5.5µg/ml). After 3 months of treatment, nitric oxide levels had significantly increased from 64.5±6.6µmol/l to 104±15.4µmol/l, and remained significantly elevated at 6 months. Asymmetric dimethylarginine and 8-hydroxydeoxyguanosine levels did not change during the 6-month treatment course, and no patients exhibited hypoglycemia or other significant adverse effects. Linagliptin treatment significantly changed various markers of inflammation relevant to the atherosclerosis in malnutrition-inflammation-atherosclerosis syndrome. Therefore, linagliptin monotherapy has pleiotropic effects on inflammation in hemodialysis patients with diabetes, and may improve their prognosis. |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
関連識別子 |
10.15369/sujms.28.9 |
| 出版者 |
|
|
出版者 |
Showa University Society |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0915-6380 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
S28_9.pdf (194.4 kB)
